MedTrace Logo

Descemet Endothelial Thickness Comparison Trial II

NCT05275972 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-05-08

No results posted yet for this study

Summary

Descemet Endothelial Thickness Comparison Trial (DETECT) II is a multi-center, outcome assessor-masked, placebo-controlled clinical trial randomizing 60 patients with Fuchs endothelial dystrophy to DMEK versus Descemet Stripping Only (DSO) with adjunctive Ripasudil.

Conditions

  • Fuchs
  • Fuchs Dystrophy
  • Fuchs' Endothelial Dystrophy

Interventions

DRUG

Ripasudil

Topical Ripasudil 0.4%

DRUG

Placebo

Topical Placebo

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • University of California, San Francisco

    collaborator OTHER

  • University of California, Davis

    collaborator OTHER

  • Case Western Reserve University

    collaborator OTHER

  • Dartmouth-Hitchcock Medical Center

    collaborator OTHER

  • University of Pennsylvania

    collaborator OTHER

  • University of Miami

    collaborator OTHER

  • Wills Eye Hospital

    collaborator UNKNOWN

  • Devers Eye Institute

    collaborator OTHER

  • Stanford University

    lead OTHER

Principal Investigators

  • Jennifer Rose-Nussbaumer, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-23
Primary Completion
2027-11-30
Completion
2028-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05275972 on ClinicalTrials.gov